BMS, Transgene to test new lung cancer combination therapy
Bristol-Myers Squibb and Transgene are to test a potential new therapy for advanced non-squamous non-small cell lung cancer (NSCLC) combining a PD-1 immune checkpoint inhibitor, vaccine and chemotherapy.
Read More
